AnX Robotica

AnX Robotica

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $44M

Overview

AnX Robotica is an innovative private company pioneering AI-enhanced capsule endoscopy for gastrointestinal diagnostics. Its core platform, NaviCam®, includes systems for the small bowel, esophagus, and whole-gut transit testing, augmented by its proprietary ProScan™ AI software which dramatically reduces image reading time. The company is commercial-stage, with its lead product already FDA-cleared and in clinical use, targeting the large and growing market for efficient, non-invasive GI diagnostic solutions. AnX Robotica represents a convergence of medical device engineering and digital health AI, aiming to improve workflow efficiency and diagnostic accuracy for physicians.

Gastroenterology

Technology Platform

Integrated capsule endoscopy hardware (for small bowel, esophagus, motility) combined with proprietary AI software (ProScan™) for automated image analysis and diagnostic assistance.

Funding History

3
Total raised:$44M
Series A$15M
Series A$26M
Seed$3M

Opportunities

The company addresses a large and growing market for minimally invasive GI diagnostics, with a unique first-mover FDA-cleared AI tool that solves a major workflow pain point for clinicians.
Expansion into esophageal visualization and motility testing significantly broadens its total addressable market beyond small bowel endoscopy.

Risk Factors

Key risks include competition from large, established medtech players, the challenge of changing clinical workflows and securing reimbursement, and the execution risk associated with commercializing multiple new products in a capital-intensive private company environment.

Competitive Landscape

AnX competes in the capsule endoscopy market against large incumbents like Medtronic (Given Imaging) and Olympus, who have broader product portfolios and extensive sales forces. Its key differentiator is its FDA-cleared ProScan™ AI, though competitors are actively developing similar AI capabilities. In motility, it would compete against older diagnostic standards and other emerging technologies.